SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics and Prognostics Toward Commercialization (R44) | Apply Online

Opportunity Summary:

The SBIR Phase IIB Bridge Awards FOA (RFA-CA-15-010), titled "SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics and Prognostics Toward Commercialization (R44)," is a National Institutes of Health opportunity (through the National Cancer Institute) designed to help small businesses push promising, already-funded cancer technologies from late-stage development into commercialization. It specifically targets projects that have previously received an SBIR or STTR Phase II award from any federal agency and now need additional support for the next, typically more expensive steps required to reach a market-ready product or service. In practical terms, this program is meant to bridge the gap between successful Phase II research and the point where a technology can attract sufficient market adoption, regulatory clearance or approval where relevant, manufacturing scale-up, and real-world deployment.

The FOA is focused on three broad categories of cancer-related innovation. First, it supports cancer therapeutics, which can include drug candidates, biologics, targeted therapies, or other treatment modalities that still require substantial work to reach key value-inflection points. Second, it supports cancer imaging technologies, interventional devices, and in vivo diagnostics, covering tools used in living patients such as imaging platforms, device-based interventions, and diagnostic approaches that operate in the body. Third, it supports in vitro and ex vivo cancer diagnostics and prognostics, which generally includes tests run on patient samples (for example, blood, tissue, or other biospecimens) that help detect cancer, guide therapy, or predict outcomes. The common thread across these areas is that projects should be beyond early feasibility and positioned for the final development push needed to become commercially viable.

A central feature of this Bridge Award is the expectation of meaningful private-sector participation. The FOA is structured to promote partnerships between SBIR/STTR Phase II awardees and independent third-party investors and/or strategic partners, such as venture capital firms, angel investors, corporate partners, or other non-federal sources of capital and support. Applicants are required to include a Commercialization Plan (consistent with SBIR Phase II application requirements under the SF424 instructions), and that plan must spell out the companys path to market, including what outside funding has already been secured or is expected during the project period. Importantly, the FOA sets a strong expectation that third-party investor funding will be equal to or greater than the NCI funds requested over the Phase IIB Bridge Award period. This is meant to ensure the project has both technical momentum and financial backing, and that federal dollars are being used to catalyze near-term commercialization rather than extend basic R and D indefinitely.

From a development standpoint, the FOA allows flexibility in what stage of work is proposed as long as it fits the goal of commercialization. Projects may address preclinical development (such as advanced validation, optimization, safety studies, usability engineering, assay refinement, or preparation for regulatory interactions) and/or clinical development. Clinical trials can be included when appropriate, but they are not required, which makes the mechanism relevant for both companies preparing to enter the clinic and those already planning clinical evaluation as part of a clear commercialization strategy.

On the administrative side, this is a discretionary grant using the R44 activity code (SBIR). The FOA anticipated roughly 10 awards, with an estimated total funding level of about $10,000,000 and an award ceiling of $1,000,000 per award. There is no cost sharing or matching requirement stated as a formal grant requirement, but the program effectively expects substantial third-party investment as part of the bridge model described above. Eligible applicants are U.S. small businesses; non-U.S. entities and non-U.S. components of U.S. organizations are not eligible to apply, although foreign components (as NIH defines them in its Grants Policy Statement) may be allowable in certain circumstances. The FOA was posted March 13, 2015, with an application deadline of May 13, 2015, and it was later archived (June 13, 2015). The opportunity is associated with CFDA program areas 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research), reflecting its coverage across both diagnostic and therapeutic innovation.

Overall, the program is best understood as a commercialization-focused extension for strong SBIR/STTR Phase II projects in oncology, where the remaining work is expensive and execution-heavy and where outside capital and partnerships are essential. The governments role here is to reduce risk at a critical transition point, encourage investor and strategic partner engagement, and help move cancer-related technologies into the market where they can have real clinical and public health impact.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Lower Atmosphere Observing Facilities

Previous opportunity: Improving Isoniazid Preventive Therapy Penetration through Intensification of Case Findings at the Community Level in Rural South Africa under PEPFAR

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA CA 15 010

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA CA 15 010) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 15 010", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.